1. Home
  2. > Healthcare
  3. > Pathology Market Trends
Hepatitis Drugs Global Market Report 2022

Hepatitis Drugs Global Market Report 2022

  • September 2022
  • 175 pages
  • ID: 6319268
  • Format: PDF
  • The Business Research Company

Summary

Table of Contents

Major players in the hepatitis drugs market are Gilead Sciences Inc, F Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co Inc, GlaxoSmithKline PLC, AbbVie Inc, Novartis AG, Bristol-Myers Squibb Company and Dynavax Technologies Corporation.

The global hepatitis drugs market is expected to grow from $17.12 billion in 2021 to $17.47 billion in 2022 at a compound annual growth rate (CAGR) of 2.07%. The market is expected to grow to $21.68 billion in 2026 at a compound annual growth rate (CAGR) of 5.55%.

The hepatitis drugs market consists of the sale of hepatitis drugs products by entities (organizations, partnerships, and sole proprietors) that are used to treat various types of hepatitis referring to liver inflammation.The hepatitis damages the liver causing swelling and damage affecting liver functions.

The medications used to treat hepatitis, are a viral infection of the liver. These medications aid in the reduction of liver inflammation as well as the prevention of liver cell damage.

The main type of hepatitis drugs interferon alphas, HIV NRTIS, nucleotide polymerase / NS5A inhibitor combinations, hepatitis C protease / NS5A inhibitor combinations, NS5A inhibitors, nucleotide polymerase inhibitors, nucleoside analog antivirals and thrombopoiesis stimulating agents.The interferon alphas are the innate immune system in response to environmental exposures such as viral infections.

Interferon alpha has been developed in different formulations for the treatment but mainly for chronic hepatitis C.The drugs are consumed through oral or injection route of administration and are distributed through channels such as hospital pharmacies, retail pharmacies and online pharmacies.

These drugs are used to treat hepatitis A, hepatitis B, hepatitis C, hepatitis D and hepatitis E.

North America was the largest region in the hepatitis drugs market in 2021.Asia Pacific is expected to be the fastest-growing region in the forecast period.

The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The hepatitis drugs market research report is one of a series of new reports that provides hepatitis drugs market statistics, including hepatitis drugs industry global market size, regional shares, competitors with an hepatitis drugs market share, detailed hepatitis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis drugs industry. This hepatitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The increasing number of cases of different types of hepatitis is significantly driving the growth of the hepatitis drugs market.Various types of hepatitis need different drugs for treatment and this increases the demand for hepatitis drugs.

According to World Health Organization (WHO), in 2019, 296 million people had chronic hepatitis B infection, with an average of 1.5 million new infections every year. This increasing number of hepatitis infections will invariably increase the need and consumption of hepatitis drugs. Thus, the increasing number of different types of hepatitis is expected to propel the growth of hepatitis drugs in the forecast period.

New product launches are a significant trend in the hepatitis drugs market.The key players in the hepatitis drugs sector are focusing on launching new products for hepatitis treatments to strengthen their position in the market.

For instance, in September 2020, MYR Pharmaceuticals, a Germany-based biotechnology company launched HEPCLUDEX (bulevirtide) in Germany, France, and Austria for the treatment of chronic hepatitis B and D.HEPCLUDEX® is the first European drug to be approved for the treatment of chronic hepatitis D.

HEPCLUDEX® inhibits the entry of HBV/HDV into hepatocytes and viral spread within the liver by blocking the NTCP receptor on the surface of hepatocytes.

In March 2021, Gilead Sciences, a US-based biopharmaceutical company acquired MYR GmbH for cash consideration of $1.55 billion (€1.45 billion). As a result of the acquisition, Gilead leverages the MYR GmbH’s new drugs and expansion of the market globally in providing better treatment for hepatitis. MYR GmbH is a Germany-based company that develops inhibitors for chronic hepatitis B and D infections.

The countries covered in the hepatitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Specialty Generics Market Research Report by Type, Application, End-Use, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

  • $ 3949
  • January 2023
  • 152 pages

Specialty Generics Market Research Report by Type (Injectables and Oral Drugs), Application, End-Use, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States ...

  • United States
  • Marketing Research
  • Advertising
  • Industry analysis
  • Generic Drugs Market Share

ref:plp2022

Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on